Thomson Reuters
   Advanced Search
  About Scientific Scientific Press Room Contact Scientific   EN : JP : CN : KR : ES : PT   
 

 
Gazette Highlights News 2006

Click on a week to view more

Week 52:
  • The two “new” SPC applications reported in the December 27th Patents and Designs Journal (PDJ) are those from Pfizer and Southern Research Institute (SRI)...
  • Oxford Biomedica is seeking patent protection for methods and compositions for T cell receptors which recognize the 5T4 antigen...
  • Diosamine Development Corporation, or DDC, an eponymous California-based company is developing Diosamine which is described as a “very promising pharmaceutical drug candidate"...
  • e-Therapeutics Limited has filed a patent application for treatment of multi-drug resistant bacterial infection...
  • GSK companies have a handful of new applications including one relating to a sheet driver for use in a drug dispenser...
  • Norbrook Laboratories has filed an initial “A0” filing with the UK patent office for a process for the purification of meloxicam...
  • Nordic Biosciences has filed a patent application for diphyllin and other lignans for the treatment of V-ATPase mediated diseases...
  • UK initial (“A0”) applications filed November 15th - 21st 2006
Week 51:
  • News that Celegene has purchased a plant in Switzerland from Siegfried serves to focus attention on the New Jersey-based company’s Revlimid product...
  • “Disappointed” was AstraZeneca’s perhaps rather understated reaction to the December 19th news that the European Patent Office had rejected EP652872, the case in which esomeprazole magnesium...
  • In its December bulletin, Societa Italiana Brevetti (SIB) reports that plans to create a single patent jurisdiction for all EU member states received a major setback recently...
  • The PDJ (No 6135) reports the expiry of Bristol-Myers Squibb’s SPC on EP0053902 for fosinopril + hydrochlorothiazide (Monopril HCT)...
  • UK initial (“A0”) applications filed November 7th - 14th 2006
Week 50:
  • The Australian Official Journal (20/48) this week reports the filing of five applications for extensions of term...
  • Of these, Gilead Sciences has been granted a term extension for adefovir dipivoxil (Hepsera)...
  • The Journal also reports the acceptance of an extension on AU618989 filed by the British Technology Group for alemtuzumab (MabCampath)...
  • The applications for term extension filed are based on AU580151 (Ustav Organicke Chemie a Biochemie Akademie ved Ceske Republiky)...
  • The UK Patents and Designs Journal (PDJ No. 6134) contains no SPC events this week. However the PDJ does announce the revocation of Bayer Healthcare’s EP0764447, which details a method for the production of immune globulin intravenous (human) (IGIV)...
  • A relatively rare occurrence that we can report this week, is the filing of an SPC application in Iceland...
  • UK initial (“A0”) applications filed October 31st – November 6th 2006
Week 49:
  • As previously reported in the Current Patents Gazette issue 0646 the PDJ has now published the SPC application for a live attenuated varicella-zoster virus (VZV), particularly the Oka strain made by Merck & Co...
  • Prior to publication in the PDJ, we can report that two new SPC applications have been filed at the UK Patent Office. The first SPC application by Pfizer, covers cefovecin, (Convenia)...
  • The second SPC application was filed by the Southern Research Institute and covers clofarabine,...
  • The Japanese Patent Gazette for November, which we received this week, contained no new granted patent extensions although new applications were reported for one veterinary and three human drugs...
  • In the light of last weeks discontinuation by Pfizer of the development of torcetrapib, including the combination with atorvastatin...
  • Chroma Therapeutics Ltd filed a UK initial (“A0”) patent application this week, seeking protection for eight enzyme inhibitor applications...
  • UK initial (“A0”) applications filed October 23rd - 31st 2006
Week 48:
  • Ahead of publication in the PDJ, Current Patents Gazette (CPG) issue 0645 reported that Shire Pharmaceuticals Contracts Limited had lodged an SPC for Fosrenol on 27th October 2006...
  • Also published in the PDJ this week, three weeks after initial report in issue 0645 of the Current Patents Gazette (CPG); Merial Limited has lodged an SPC covering Selamectin...
  • In Hungary, Orion Corp has been granted an SPC for levosimendan...
  • Following the report in last weeks CPG (No. 0647) that Novartis had been granted an SPC in Germany for darifenacin on EP0850059...
  • Advanced Biomedical Ltd is seeking protection for “multiple assays”. This will be the fifth PCT application to emerge assigned to this company, which became incorporated in 2003 in a merger of Peptide Products Ltd (est.1989)...
  • UK initial (“A0”) applications filed October 18th - 24th 2006
Week 47:
  • Rhone-Poulenc Agriculture Ltd’s SPC for a combination comprising diflufenican and terbuthylazine entered into force...
  • The German Patent Gazette for this week (Patentblatt 2006/47), however, contains two pharmaceutical SPC applications and four granted pharmaceutical SPCs as well as four agrochem applications...
  • NPS Pharmaceuticals were granted an SPC for cinacalcet, a first-in-class calcimimetic for treatment of secondary hyperparathyroidism (sHPT), which was outlicensed to Amgen.
  • Expiring earlier in 2019 is the granted SPC for palifermin (Kepivance) awarded to Chiron on DE69434053...
  • The biggest drug gaining SPC protection was etanercept, co-marketed by b (formerly Immunex) and Wyeth as Enbrel,...
  • Orion Genomics has announced a notice of allowance of a key patent application covering the company’s MethylScope technology,...
  • UK initial (“A0”) applications filed October 9th - 16th 2006
Week 46:
  • As previously reported in the Current Patents gazette issue 0643, Wyeth Holdings Corporation has lodged an SPC for Tigecycline...
  • The PDJ also reports that the Sloan-Kettering Institute for cancer research has lodged an SPC covering the purine nucleoside, clofarabine...
  • The Current Patents gazette issue 0644 also reported that NPS Allelix Corp. was seeking SPC protection for an injectable formulation of recombinant human parathyroid hormone (PTH)...
  • The PDJ also reports that SPCs have entered into force for Dainippon Pharmaceutical’s sparfloxacin and orbifloxacin...
  • Ahead of publication in the PDJ, Merck & Co has lodged an SPC based on EP0651789 on the 8th November 2006, which covers the method of producing a vaccine using a live attenuated varicella-zoster virus (VZV)...
  • MNL Pharma has filed an application for antimyotic agents. The company is currently developing MNLP-24, a plantderived immunostimulatory imino sugar that stimulates C-type lectins...
  • Peakdale Molecular has lodged an application entitled “Compounds”. Peakdale is a drug discovery company providing custom synthesis and contract research services...
  • UK initial (“A0”) applications filed October 3rd - 10th 2006
Week 45:
  • The UK Patents and Designs Journal (PDJ No. 6129) contains no SPC events this week but we can report the filing of two new SPC applications ahead of publication in the PDJ. Shire Pharmaceuticals have filed for an SPC covering Fosrenol,...
  • The second SPC application was filed by Merial on EP379341 and covers the selamectin veterinary product developed and marketed by Pfizer as Stronghold...
  • In last week’s Current Patents Gazette (CPG Issue 0644), we reported on granted Japanese patent extensions...
  • Pfizer led the way with six applications on four patents. Two applications of 4.75 years were filed on JP3176630, the product patent, which if granted would protect linezolid...
  • Chugai filed a five year extension request on JP3068033 which if granted would protect Roche’s epoetin beta, marketed as Epogin, Recormon or Neorecormon,...
  • Gilead Sciences applied for an extra five years protection on JP06015475 and JP2958774 for AmBisome,...
  • UK initial (“A0”) patent applications filed September 26th – October 3rd 2006
Week 44:
  • The PDJ reports that Sanofi-Synthelabo’s UK SPC for mizolastine has entered into force as from the 02nd September 2006...
  • Ahead of publication in the PDJ, Current Patents Gazette can report that Sloan-Kettering Institute for cancer research has filed a UK SPC for clofarabine...
  • NPS Allelix Corporation has filed a UK SPC for an injectable formulation of recombinant human parathyroid hormone (PTH),...
  • We have received information this week from the Società Italiana Brevetti (SIB) that Italy’s draft Financial Law 2007, to be discussed in Parliament before final approval, contains a provision aiming to reintroduce the government fees for patents, utility models and designs...
  • The Japanese Gazette for October, also received this week, contained details of 11 granted patent extensions. Pfizer received the greatest number of grants...
  • Merck & Co. were granted two extensions of five years on each of JP2742409 and JP3058351...
  • The remaining extension was granted to Eli Lilly for raloxifene hydrochloride...
  • UK initial (“A0”) applications filed September 19th - 26th 2006

Week 43:
  • The PDJ this week (No. 6127) reports that The US Government’s SPC for didanosine entered into force on the 22nd August 2006...
  • Also reported in the PDJ this week was that the US commerce’s SPC for zalcitabine also entered into force on the 21st August 2006...
  • The PDJ also reported the expiration of Warner-Lambert’s SPC on moexipril...
  • Wyeth Holdings have also filed an application recently requesting an SPC for tigecycline...
  • The new EU regulation on medicinal products for paediatric use has passed its final legislative hurdle...
  • UK initial (“A0”) applications filed September 13th - 19th 2006
Week 42:
  • The PDJ this week (No. 6126) contains no pharmaceutical SPC information, but reports that Mallinckrodt Veterinary's Supplementary Protection Certificate (SPC)...
  • BioDiscovery Inc, a company developing software to revolutionize drug discovery and diagnostics through analyzing data produced by high-throughput microarray technology...
  • In the Australian Official Journal of Patents this week (volume 20, number 40) the University of Queensland is reported to have filed for a term extension...
  • Amarin Corp announced the grant of US7119118 (WO0044361) covering the use of its proprietary ultra-pure ethyl-EPA compound, Miraxion...
  • Vanilla: A patch on viagra?
    A non-transdermal "scratch n' sniff" patch containing ethyl vanillin went on sale as SFM to combat reduced male libido...
  • UK initial (“A0”) applications filed September 6th - 12th 2006
Week 41:
  • The Patents and Designs Journal this week (No. 6125) reports that Genentech's SPC for pegvisomant was granted...
  • The PDJ also reports that Pfizer has been granted an SPC for erlotinib, in particular the hydrochloride salt...
  • US sales for erlotinib (Tarceva) reported by Genentech for 2005 totalled $274.9 million...
  • Acure Pharma AB has filed a UK initial ("A0") application entitled compositions and methods for the treatment of neurological damage...
  • Receptors and ion channels have formed the basis for patenting by Paradigm Therapeutics, but the company's transition to protection of novel therapeutics began earlier in 2006...
  • Alpharma ApS is seeking protection for an application claiming purification of mupirocin...
  • UK initial ("A0") applications filed August 29th - September 6th 2006

Week 40:
  • The Patents and Designs Journal this week (PDJ 6033) reports that Pfizer’s SPC for the veterinary product, danofloxacin (Advocin),...
  • In the news this week has been Genentech’s Lucentis, which was approved in the USA in June 2006 as a treatment for neovascular (wet) age-related macular degeneration (AMD)...
  • Oxford Genome Sciences a privately held biotechnology company focused on the development of personalized medicines, has filed 5 UK initial (“A0”) applications entitled “protein”...
  • NovaThera Limited, an Imperial College London spin-out, has filed for composite material...
  • UK initial (“A0”) applications filed August 22nd - 29th 2006
Week 39:
  • There are no SPC events recorded in the UK Patents and Designs Journal (PDJ 6123) this week. However, we have received the Japanese patent gazette published September 25...
  • The extension is granted to the Beecham Group PLC (now GlaxoSmithKline) and provides a five year extension on granted Japanese patent JP06047587 for paroxetine...
  • Angiomed GmbH & Co Medizintechnik KG has filed an UK initial (“A0”) application for a self-expanding stent...
  • BiotechGen Ltd has filed three applications this week, all relating broadly to the use of molecules for the treatment of disease (unspecified) and screening methods...
  • Cambridge Consultants Ltd has added to their extensive portfolio of inhalers with an application entitled drug capsules for dry powder inhalers...
  • UCB S.A. is seeking protection for a selection of “therapeutic agents” this week. UCB has a strong product line in CNS (Keppra® (levetiracetam), Nootropil® (piracetam) and Metadate-CD™ / Equasym™ (methylphenidate HCl))...
  • KU Leuven Research & Development is seeking protection for a “Novel therapy for joint disorders”...
  • UK initial (“A0”) applications filed August 16th - 21st 2006
Week 38:
  • The PDJ this week (No. 6122) reports that Novo Nordisk’s SPC for insulin aspart (NovoLog®; NovoRapid®) entered into force on 29 August 2006...
  • The PDJ also reports that E R Squibb & Sons Inc (now BMS) has filed an SPC for entecavir (Baracludeä), a viral replication inhibitor,...
  • An SPC has been filed by E.I. du Pont de Nemours and Co for plant protection products comprising proquinazid...
  • A defining moment in Altana’s history: In September 2006, Altana announced its plans to sell Altana Pharma AG to Nycomed...
  • UK initial (“A0”) applications filed August 8th - 15th 2006
Week 37:
  • There are no SPC events reported in the UK PDJ (No. 6121) this week. However we have recently received the Japanese Gazette for August, which contained details of eighteen granted extensions on nine patents covering six pharmaceutical products. Six extensions covered AstraZeneca's Crestor...
  • Actemra (tocilizumab) launched in Japan for the treatment of Castleman's disease by Chugai, together with parent company Roche, also received six extensions...
  • Novartis were granted two five year extensions for letrazole and its use in treating post-menopausal breast cancer...
  • UK initial (“A0”) applications filed August 2nd - 7th 2006
Week 36:
  • The Patents and Designs Journal this week (6120) reports the filing of and SPC by Sanofi-Aventis for its central cannabinoid CB1 receptor antagonist, rimonabant (Acomplia)...
  • The PDJ also reports that PDL Biopharma and Fred Hutchinson Cancer Research Center have each filed an SPC for natalizumab (Tysabri®)...
  • Nippon Soda has filed an SPC for the agrochemical product acetamiprid...
  • Prosidion Limited, the wholly owned UK subsidiary of OSI (Prosidion) has filed a UK initial (“A0”) application entitled “amide derivatives"...
  • Cardiff based Assaymetrics Limited has filed an application for fluorogenic peptides and their method of production...
  • ProImmune Limited has filed an application entitled “biotinylated MHC complexes and their uses”. This appears to be related to the company’s biotin-labeled Pro5® MHC class I Pentamers...
  • Istituto Superiore di Sanita (ISS) has lodged a UK initial application on “complex for use in vaccines”. The Italian National Institute of Health has several prior applications relating to vaccines to combat adenoviral infections eg HIV and HSV...
  • Procure Therapeutics Limited has filed an application entitled “stem cell marker 5”. Based on the research of Prof. Norman Maitland and his team at the University of York...
  • UK initial (“A0”) applications filed July 25th - August 1st 2006
Week 35:
  • The Patents and Designs Journal this week (No. 6119) reports that BMS’ SPC for a cefepime acid addition salt e.g. cefepime dihydrochloride (Maxipime®), entered into force on 4th August 2006...
  • The PDJ also reports the filing of an SPC by Elan for natalizumab, based on EP804237...
  • An SPC has been filed by GSK Biologicals for a live attenuated rotavirus...
  • Ahead of publication in the PDJ, we report that E R Squibb & Sons Inc (now BMS) has filed an SPC for entecavir (Baracludeä)...
  • Haptogen Limited, an Aberdeen University spin-out established in 2002, has filed a UK initial (“A0”) application for antitestosterone antibodies...
  • Melys Diagnostics has filed an application claiming a method and apparatus for analyte measurement...
  • UK initial (“A0”) applications filed July 18th - 25th 2006
Week 34:
  • The Patents and Designs Journal (6118) reports three SPC filings this week, all of which were reported three weeks ago in Gazette 0631. Cubist Pharmaceuticals has filed an SPC for daptomycin. Cubist (under license from Lilly) and its licensee Novartis...
  • An SPC has been filed by Lohmann Therapie-Systeme and Schwarz Pharma for rotigotine, based on EP1033978, assigned to LTS Lohmann and Discovery Therapeutics...
  • Alza has filed an SPC for its fentanyl iontophoretic transdermal system (IONSYS™), indicated for the management of acute pain during hospitalization...
  • This weeks PDJ also reports that a claim for revocation of Lundbeck’s European Patent EP0347066, was filed at the UK High Court on July 13th 2006 (Claim No. HC06C02767). EP0347066 which is the patent protecting escitalopram...
  • Amura Therapeutics has filed eight UK intial (“A0”) applications this week, seven entitled compounds and one process. In May 2006, the Cambridge-based biotech company merged with Proteom Ltd...
  • Britannia Pharm Ltd is seeking protection for injectable pharmaceutical compositions containing panthenol...
  • UK initial (“A0”) applications filed July 11th - 18th 2006
Week 33:
  • The Patents and Designs Journal this week (No. 6117) reports the filing of Gilead Science’s SPC for Pagatanib (Macugen®), an angiogenesis-inhibiting anti-VEGF165 aptamer...
  • An SPC granted to Pfizer for doramectin, a veterinary product, entered into force on 23rd July 2006...
  • The PDJ also reports the entry into force of three SPCs for plant protection products. Two SPCs for herbicide products, granted to Rhone-Poulenc Agriculture...
  • Ahead of publication in the PDJ we report that an SPC has been filed by GSK Biologicals for a live attenuated rotavirus...
  • PDL Biopharma and Fred Hutchinson Cancer Research Center have each filed an SPC for natalizumab. Last week (Gazette 0632) we reported the filing of another SPC for natalizumab by Elan Phamaceutical...
  • Glaxo Group Ltd has filed three UK initial applications this week, one for a counter and recorder for a pill dispenser and two others claiming novel compounds...
  • UK initial (“A0”) applications filed July 4th - 11th 2006
Week 32:
  • The UK Patents and Designs Journal (No.6116) contains no SPC information this week. However, ahead of publication in the PDJ, we report the filing of Elan Phamaceutical’s SPC for natalizumab (Tysabri, formerly Antegren)...
  • The PDJ also contains details of three applications for revocation lodged at the Patents Court by Teva Pharmaceuticals on EP639976 (assigned to Merrell Dow Pharmaceuticals), covering Allegra (fexofenadine) tablets...
  • The Japanese Patent Gazette for July contained details of three term extensions granted on JP2082519 for olmesartan medoxomil and its use in treating hypertension...
  • Further 5 year extension applications were filed by Daiichi Pharma for the use of levofloxacin (Cravit) in treating various infections...
  • Sanofi-Aventis have also applied for a five year extension on JP2949366 for clopidogrel sulphate (Plavix) which will expire October 2015 if granted...
  • UK initial (“A0”) applications filed June 27th - July 4th 2006
Week 31:
  • The Patents and Designs Journal this week (No. 6115) reports that Shire Pharmaceutical’s Supplementary Protection Certificate (SPC) for balsalazide disodium (Colazide) expired on 6th July 2006...
  • The PDJ also reports the entry into force of Pharmacia’s SPC for exemestane (Aromasin), a steroidal aromatase inhibitor...
  • Ahead of publication in the PDJ, we report the filing of three SPCs. Alza Corporation has filed an SPC for its IONSYS Fentanyl Iontophoretic Transdermal System...
  • An SPC for daptomycin has been filed by Cubist Pharmaceuticals. Cubist (under license from Lilly) and its licensee Novartis...
  • LTS Lohmann Therapie-Systeme and Schwarz Pharma Ltd have filed an SPC application for rotigotine...
  • Vicuron Pharmaceuticals has filed a PCT application (WO2006080920) for a lantibiotic named Antibiotic 107891 and its Factors A1 and A2 this week...
  • UK initial (“A0”) applications filed June 20th - June 27th 2006
Week 30:
  • The Patents and Designs Journal (No. 6114) contains no pharmaceutical SPC information this week, but reports that Rhone-Poulenc Agriculture’s SPC...
  • Prior to its publication in the PDJ, we report that Giles Sciences has filed an SPC for pegaptinib (Macugen®)...
  • Immtech Pharmaceuticals Inc. announced that the USPTO had issued US07071338, equivalent to WO2004051217 in ThomsonPharma...
  • On the 27th July 2006 the Munich-based drug discovery and development company, 4SC AG, was informed by the US patent and trademark office (USPTO) that it had been granted US07071355. The patent relates to novel heterocyclic amine derivatives as dihydrooratate dehydrogenase (DHODH) inhibitors...
  • Argenta Discovery Limited is seeking protection for 2-oxo-2H-chromene derivatives...
  • UK initial (“A0”) applications filed June 13th - June 19th 2006
Week 29:
  • The UK Patents and Designs Journal this week (No. 6113) reports the entry into force in June 2006 of an SPC granted to Novo Nordisk for tiagabine...
  • Forest Laboratories and H.Lundbeck have filed suit against Caraco Pharmaceuticals over Lexapro (escitalopram)...
  • Janssen, Ortho-McNeil Neurologics and Synaptech have filed suit against Barr Pharmaceuticals in relation to patent protection for the drug Razadyne...
  • On Jul 12, 2006 Critical Therapeutics, Inc (CTI) announced that US20030113323, the equivalent of WO00047104, which is reported in ThomsonPharma, was granted as US7060504. The patent relates to “antagonists of HMG1 for treating inflammatory conditions”...
  • UK initial (“A0”) applications filed June 7th - June 13th 2006
Week 28:
  • The Patents and Designs Journal this week (No. 6112) reports that Genetics Institute (now Wyeth BioPharma) has been granted an SPC for dibotermin alfa, a recombinant human bone morphogenetic protein-2...
  • An SPC granted to Daiichi Pharm for levofloxacin, based on EP0206283, has entered into force and will extend protection until 19th June 2011. Several SPCs have been granted for levofloxacin...
  • The PDJ also reports the entry into force of Novartis’ SPC for fludioxonil...
  • Syntaxin Limited and Allergan Inc have jointly filed two UK intial (“A0”) applications concerned with the treatment of pain. The two companies have other joint patent property...
  • Although part of the ProStrakan Group since September 2004, ProSkelia SAS continues to file patent applications in that name...
  • UK initial (“A0”) applications filed May 30th - June 6th 2006
Week 27:
  • Astellas received five year extensions on two patents (JP03038276 and JP0346445) for tacrolimus (Prograf) used in treatment of rheumatoid arthritis...
  • Related companies Taiho and Otsuka Pharmaceuticals also received additional five year extensions (on JP2538422 and JP2614164) for Taiho’s oral anticancer combination TS-1 (S-1 or Cefasone)...
  • Amongst others receiving additional extensions were Sanofi-Aventis who were granted 4 years six months and 28 days extension for docetaxel hydrate on...
  • Extensions of 2 years 17 days and three years were granted to Stichting Rega (on JP3164385) and Gilead Sciences (on 3573713) for adefovir pivoxil used in combination with lamivudine...
  • King Pharmaceuticals received a five year extension for an adenosine formulation on JP2914454...
  • Three five year extensions which expire April 25, 2016 were granted on JP2686863 to Kissei Pharmaceutical for mitiglinide calcium hydrate (Glufast)...
  • Extensions were also granted to Meito Sangyo on JP2939336 for their ferucarbotran liver contrast agent, to Taisho Pharmaceuticals...
  • Nine extension applications were submitted by Otsuka for schizophrenia treatment, aripiprazole (Abilify)...
  • Finally, Serono requested two five year extensions on JP2523843 for Gonal-F (follitropin alfa)...
  • UK initial (“A0”) applications filed May 23rd - 30th 2006
Week 26:
  • The Patents and Designs Journal this week (No. 6110) reports that Schering Biotech’s SPC for molgramostim (Leukomax®) lapsed on the 17th November 2005 because the annual fees were not paid. Based on EP0202300...
  • An SPC granted to E I DuPont de Nemours & Co for the herbicide, triflusulfuron methyl entered into force on 6th June...
  • This week has seen the long anticipated launch of rimonabant (June 28th), better known to dieters across the nation as Acomplia. Sanofi-Aventis’ anti-obesity drug...
  • An ever increasing trend has been emerging in “reviving” or “re-profiling” old drugs that have failed in late stage trials or have been successfully marketed for a different indication, indicating that it is not only yesterdays tin-cans and newspapers that are proving popular targets of recycling nowadays. Arakis Limited is seeking protection for three applications, entitled raceimisation and recycling process...
  • UK initial (“A0”) applications filed May 16th - 23rd 2006
Week 25:
  • The Patents and Designs Journal (No. 6109) contains no pharmaceutical SPC information this week but reports the expiry of FMC Corporation’s SPC, for the herbicide clomazone...
  • Also recorded in the PDJ is the entry into force of an SPC granted to the Commonwealth Scientific and Industrial Research Organisation (CSIRO), for Gallivac HVT IBD...
  • Ranbaxy announced this month that it had entered a strategic alliance with Zenotech, in which it is to exploit its market influence regarding eleven of Zenotech’s oncology candidates within the US and Canadian territories...
  • Several new programs have been published this week, in addition to Merck & Co’s first microsomal prostaglandin E synthase 1inhibitors, which indicates a change in tack from the upstream COX2 inhibitors previously investigated...
  • Carlsson research published US20060135531 on substituted piperidinebased dopamine modulators for the treatment of CNS disorders including schizophrenia and Huntington’s...
  • UK initial (“A0”) applications filed May 8th - 15th 2006
Week 24:
  • A proposal for a European regulation on medicinal products for paediatric use moved closer to approval this week. The aim of this proposal is to “address the conditions required for the development of paediatric medicines notably by supporting innovation and research and by creating incentives for pharmaceutical companies...
  • This week’s Patents and Designs Journal (No. 6108) reports the filing of an SPC by Sankyo for olmesartan medoxomil in combination with hydrochlorothiazide...
  • EP503785 is also the basis of SPC applications relating to the single olmesartan medoxomil product, first launched in 2002...
  • UK initial (“A0”) applications filed May 2nd - 9th 2006
Week 23:
  • The Patents and Designs Journal this week (No. 6017) reports the expiry of SPC/GB93/071, based on GB2162522, for GSK’s sumatriptan (Imitrex)...
  • GSK holds rights in most major markets and worldwide sales of sumatriptan reported by GSK for 2005 totalled $1.219 billion. According to our Strategic Drugs database (SDdb)...
  • The Japanese Patent gazette published on May 25th contains details of two granted patent extensions. Astellas were granted a five-year extension on JP05036411 for the use of tacrolimus in treatment of rheumatoid arthritis...
  • Roche Diagnostics also received a five-year extension on JP07025780 for use of zoledronic acid hydrate (Zometa 4 mg injections) in treatment of hypercalcemia caused by a malignant tumour...
  • Inovio Biomed. Corp announced that they had acquired rights to several patent families relating to the use of electroporation technology under licence from Sphergen SARL; including electroporation of nucleic acids in muscle (US6939862) and tumor tissue (US6528315)...
  • UK initial (“A0”) applications filed April 25th - May 2nd 2006
Week 22:
  • During the course of March 2006 both the Republic of Honduras and the Lao People’s Democratic Republic deposited instruments of accession to the Patent Cooperation Treaty (PCT) with WIPO, bringing the total number of PCT states to 130...
  • The Patents and Designs Journal this week (No. 6106) reports the filing of an SPC by three inventors based at the NIH and another by Amgen, for palifermin (Kepivance)...
  • The PDJ also documents the filing of an SPC by GSK for a formulation of xinafoate and 1,1,1,2-tetrafluoroethane...
  • Theragenics Corporation is reported to have filed for an SPC in the UK for Yttrium-90 glass microspheres...
  • The PDJ reports the grant of two SPCs for agrochemical products. The first is an SPC for prohexadione and its salts, granted to Kumiai...
  • An SPC granted to The General Hospital Corporation for the extension of protection of gadoxetic acid, disodium (Primovist) has entered into force...
  • UK initial (“A0”) applications filed April 18th - 25th 2006
Week 21:
  • The Ascension Day public holiday on Thursday May 25th in many European countries, including Switzerland and Germany, means that the PCT applications for week 0621 bear the publication date of the next working day, Friday 26th...
  • Aromatase inhibitors have been in the UK national news this week, following publication of preliminary advice from The National Institute for Health and Clinical Excellence (NICE). Specifically, NICE refers to the possible future use of letrozole, anastrozole and exemestane...
  • Sankyo, having received UK marketing authorization on February 14th 2006, has now filed an application for a Supplementary Protection Certificate (SPC) relating to olmesartan medoxomil...
  • Another Japanese innovator, Eisai, has a pair of PCT applications published this week aimed at further strengthening patent protection for its phase II anti-tumor candidate indisulam...
  • Axis-Shield Diagnostics Ltd has filed an application claiming an anti-factor XIIa therapy. This may be related to WO2004057343, which claims factor XIIa variants for the immunological diagnosis of thrombosis and thromboembolism...
  • UK initial (“A0”) applications filed April 10th - 18th 2006
Week 20:
  • Ahead of publication in the Patents and Design Journal, we report that three applicants, Jeffrey Rubin, Paul Finch and Stuart Aaronson have been granted SPC/GB06/015, which is estimated to extend the protection for palifermin (Kepivance) until January 2015...
  • Amgen has filed SPC/GB06/016, also for palifermin, based on its application EP785949 covering a purification process for keratinocyte growth factor...
  • SPC applications have previously been filed in Austria, the UK, France, Ireland and the Netherlands by Chiron, on EP706563 for Amgen’s palifermin...
  • GSK has filed an SPC application for a formulation of xinafoate and 1,1,1,2-tetrafluoroethane based on EP616523...
  • The PDJ this week (No. 6104) reports the entering into force of SPC/GB99/024 for zaleplon (Sonata). Zaleplon is a nonbenzodiazepine sedative developed by American Home Products (now Wyeth) for the treatment of insomnia...
  • In December 2001, Elan acquired US marketing rights to zaleplon from Wyeth. By June 2003, Elan had divested its primary care business (which included zaleplon) to King Pharmaceuticals...
  • UK initial (“A0”) applications filed April 4th - April 11th 2006
Week 19:
  • Novo Nordisk’s granted SPC/GB96/022 for recombinant coagulation Factor V11a (eptacog alfa), entered into force on 16th April 2006, as reported in the Patents and Designs Journal this week (PDJ No. 6103). Novo Nordisk’s eptacog alfa (NovoSeven) is an inactivated recombinant form of plasma coagulation Factor VIIa...
  • The PDJ also reports the entering into force of SPC/GB98/033 for Zafirlukast (Accolate). This SPC is based on AstraZeneca’s patent, EP199543, and is due to expire on 2nd January 2011 based on the earliest marketing authorization in Ireland. SPCs granted in Belgium, Italy and Luxembourg are also due to expire...
  • In last week’s Current Patents Gazette (CPG 0618) we reported on the patent extensions granted in the Japanese gazette published in April. In addition to these, five extension applications were reported on three patents. Merck & Co has requested two five year extensions on both JP2742409 and JP3058351 for finasteride...
  • In the remaining application Toyama Chemical Company requests an extension of three years, four months and eighteen days on JP3346586 for an antibacterial ophthalmic formulation comprising tosufloxacin...
  • UK initial (“A0”) applications filed March 28th - April 5th 2006
Week 18:
  • The Patents and Designs Journal No. 6102 reports the entering into force of SPC/GB99/038 for moroctocog alfa (recombinant factor VIII)...
  • Genetics Institute (GI) purchased the marketing and development rights of Pharmacia & Upjohn’s recombinant Factor VIII in August 1997...
  • Biovitrum, which produces ReFacto on contract from Wyeth, has also been granted SPCs for morocotcog alfa in several European countries...
  • Chiron and Novo Nordisk have also been granted SPCs based on EP466199 for moroctocog alfa...
  • The PDJ also reports the expiry of SPC/GB93/034 on 7th April 2006, for a formulation of sodium cromoglycate and salbutamol sulfate...
  • The April Japanese gazette reports the grant of extensions on five pharmaceutical patents. The first, on JP05080451, is the third five year extension granted to Otsuka Pharmaceutical...
  • Sepracor were granted two extensions for use of fexofenadine hydrochloride in treating pruritus...
  • Pfizer were granted an extension of two years nine months one day on JP06031300 for use of azithromycin...
  • UK initial (“A0”) applications filed March 21st - 27th 2006
Week 17:
  • The Patents and Designs Journal No.6101 reports the expiry of SPC/GB93/044 for azithromycin. The SPC covers GB2094293 assigned to Pliva
  • The Croatian company has licensed the antibiotic to Pfizer for all markets except Eastern Europe and some Asian countries...
  • Teva and Sandoz each launched their generic versions of a tablet formulation of azithromycin in November 2005 and in response to those launches, Pfizer introduced its generic azithromycin through Greenstone...
  • The PDJ also reports the expiry of Ciba-Geigy’s SPC for triclabendazole and levamisole on 3rd April 2006, based on the first marketing authorization in Ireland...
  • This week has seen several interesting new chemical entity applications published in addition to the diclofenac NO-donor analogs...
  • PTC therapeutics has published a cluster of four applications relating to clitocine analogs...
  • This week also saw the first NCEs to emerge from Reverse proteomics’ neural calcium sensor (NCS) modulator program, published in WO2006043710...
  • Finally, Aventis published WO2006044732, revealing the first small molecules from its PGD2 antagonist program...
  • UK initial (“A0”) applications filed March 14th - 21st 2006
Week 16:
  • The UK Patents and Designs Journal (No. 6100) reports the filing of two SPC applications from Novo Nordisk that were reported 3 weeks ago in Current Patents Gazette 0612. These filings both relate to EP705275, which claims ASP-B28 insulin crystals comprising insulin aspart and protamine...
  • The PDJ also reports the entering into force of SPC/GB01/045 on 26th March 2006, covering nateglinide. This SPC is based on EP0196222 assigned to Ajinomoto and is due to expire on 25th March 2011. Nateglinide (Starlix), an oral hypoglycemic agent for the treatment of type II diabetes...
  • SPC/GB93/110 granted to Astra Draco for its long-acting beta-2 adrenoceptor agonist, bambuterol, is reported to have expired...
  • A year ago (April 21, 2005), the European Court of Justice gave their decision that Swiss Marketing Authorisations should be used as the first Community Approval date, if earlier than the EU Authorisation, because of their validity in Liechtenstein...
  • York Pharma plc has filed a UK initial application claiming derivatives of 18alpha-glycyrrhetinic acid...
  • UK initial (“A0”) applications filed March 7th - 13st 2006
Week 15:
  • The UK Patents and Design Journal (PDJ No. 6099) this week reports that Biogen Idec has been granted SPC/GB04025 for ibritumomab tiuxetan (Zevalin)...
  • Corixa Corporation and licensee GSK have developed and launched a radioactive monoclonal antibody, Bexxar, which consists of infusions of the anti-CD20 antibody, tositumomab plus...
  • The General Hospital Corporation has been granted an SPC on Schering’s Gadoxetic acid disodium (Primovist)...
  • The PDJ also reports the entry into force of SPC/GB/96050, granted to H Lundbeck for patent EP200322 and sertindole...
  • UCL Biomedica in collaboration with Hamamatsu Photonics has submitted a UK initial application disclosing a cancer detection system...
  • UK initial (“A0”) applications filed February 28th - March 7th 2006
Week 14:
  • The UK Patents and Design Journal (PDJ No. 6098) reports the entry into force of SPC/GB93/036 this week, an SPC for Janssen’s patent EP196132, extending protection of risperidone (Risperdal)...
  • Last week we reported on granted patent term extensions reported in the March issue of the Japanese gazette. In addition to the granted extensions, three new extension applications were reported. The first was requested by Bayer Healthcare on JP2771853 for moxifloxacin...
  • The remaining two applications from Taiho and parent company Otsuka Pharmaceuticals requested five-year extensions on JP2614164 and JP2538422 for the TS-1 capsule (Cefasone)...
  • The University of Sheffield lodged two UK initial applications: One entitled “method” and the other on the use of RNAi inhibitory PARP activity for cancer treatment...
  • Carmen Wheatley, who appears to be new to patenting, lodged a UK initial application entitled “use of cobalamin and glutathionylcobalamin in the treatment of inflammatory disease”...
  • 4 AZA Bioscience NV has lodged a UK initial application on pteridines, for use in the treatment of IBDs...
  • UK initial (“A0”) applications filed February 22nd - 1st March 2006
Week 13:
  • The UK Patents and Design Journal (PDJ No. 6097) reports the entering into force of SPC/GB98/041 granted to Proterra for its EP193926 patent relating to rivastigmine...
  • This week’s PDJ also reports the entry into force of SPC/GB03/038 on 30th October 2005. This SPC was granted to Chiron in 2004 on its EP181150 patent relating to enfuvirtide...
  • Two further SPC applications not yet reported in the PDJ, are filings from Novo Nordisk relating to ASP-B28 insulin crystals comprising insulin aspart (IAsp) and protamine...
  • An SPC application filed by Les Laboratories Servier relating to ivabradine, reported in the Current Patents Gazette Issue 0611, has been published in the PDJ this week...
  • We recently received the Japanese Gazette for March, which records details of two granted patent extensions and three applications. The first, to Hisamitsu Medical, covers the use of diclofenac sodium...
  • Novartis have also been granted a five year extension in Japan for their zoledronic acid product, marketed as Zometa...
  • Proimmune has submitted a UK initial application on MHC binding peptides and their uses. The company has recently had published WO2005035567, disclosing chimeric MHC proteins and oligomers...
  • UK initial (“A0”) applications filed February 14th - 22nd 2006
Week 12:
  • The UK Patents and Designs Journal contains details of only one SPC event this week - the filing of the application by Pharmacia and Upjohn on EP758327 for tipranivir...
  • Three extension applications filed on separate patents in this week’s Australian Official Journal of Patents for Kepivance (palifermin) tell an interesting story. The applications were filed by Amgen...
  • Earlier this week, on March 21st-22nd, more than 150 drug industry and associated delegates gathered in Barcelona for IIR’s 5th Annual Global Generic Strategy Summit...
  • Ranbaxy’s Executive Vice-Chairman, former Glaxo executive Dr Brian Tempest made out a compelling case for India as an extremely favourable location for R&D investment...
  • The argument for locating research in India is complemented by the observation that the biggest Indian drug companies are themselves now seeking to internationalise their operations...
  • A rather different message came from the countries of Eastern and South-Eastern Europe, where per capita healthcare spending lags far behind that in the original EU states, sometimes amounting to as little as onetwentieth of the level in more developed markets...
  • K U Leuven has three UK initial filings this week entitled “Inhibition of HIV integration”. Researchers based at the Rega Institute are studying HIV-1 integration as a target for antiviral therapy...
  • UK initial (“A0”) applications filed February 7th - 14th 2006
Week 11:
  • The UK Patents and Designs Journal (PDJ No. 6095) contains only one piece of SPC information this week, the application by OSI Pharmaceuticals and Pfizer on EP817775 for the Genentech/Roche/OSI product Tarceva (erlotinib)...
  • The proposed new European regulation on providing medicinal products for paediatric use took another step forward this week. At the end of 2005, the Council of Ministers had not passed the proposal as amended by Parliament and had agreed a “Common Position”...
  • CD28-SuperMAB TGN-1412, a superagonistic monoclonal antibody that stimulates T cell generation, under development by TeGenero ImmunoTherapeutics, has been reported to have caused a severe adverse reaction in clinical trial patients this week...
  • TeGenero, a privately-owned biotechnology company based in Wurzburg is developing novel immunotherapeutics and in collaboration with Boehringer Ingelheim, was investigating TGN-1412 for the potential treatment of inflammatory diseases,...
  • reMYND NV has filed an initial UK application covering derivatives useful in treating neurodegenerative diseases. This unforgettably-named University of Leuven spin-off already has two patent applications published, both on aspects of transgenic yeast cell models...
  • UK initial (“A0”) applications filed January 31st - February 7th 2006
Week 10:
  • The UK Patents and Designs Journal only contains two items of SPC information this week, including the entry into force of a Plant Protection SPC to Novartis AG. Also included is an application by Schering Corporation for an SPC on EP0736030 covering posaconazole...
  • New SPC applications also filed in February that have not yet appeared in the PDJ include two which at first glance appear to have been filed by Pfizer. The first, on EP0817775, was filed by Pfizer Products Inc and OSI Pharmaceuticals Inc...
  • The second “Pfizer” application was filed in the name of Pharmacia and Upjohn on EP0758327 and covers tipranivir...
  • UK initial (“A0”) applications filed January 25th - 31st 2006
Week 09:
  • The Japanese Patent Gazette for February contained details of a further 15 extension applications field in 2005. These 15 applications were all filed by Takeda Chemical Industries Ltd...
  • The remaining applications were requested on JP3134187 and JP3677156 and covered the 30, 60 and 120 mg doses of Pacif, formerly known as TAK-453-SR...
  • This week, the UK Patents and Designs Journal (PDJ 6093) records the grant of an SPC to Novartis on EP0900210 for atazanavir sulphate (Reyataz)...
  • Following the filing of the last SPC application of 2005 by PDL on EP451216 for omalizumab, Genentech and Tanox have also filed SPC applications covering the same product...
  • Meditab Specialities has filed a UK initial application for the purification of citalopram...
  • Sandoz AG filed an initial UK application on January 23rd 2006 to protect an asymmetric synthesis...
  • UK initial (“A0”) applications filed January 17th - 24th 2006
Week 08:
  • The UK Patents and Designs Journal (PDJ No 6092) this week contains details of two of the SPC applications we reported in last weeks Current Patents Gazette, those to Bayer and Astellas for Profender.
  • Also reported is the entry into force on January 30, 2006 of the SPC granted to Applied Research Systems ARS Holding NV on EP211894 for rFSH (recombinant follicle stimulating hormone)...
  • The expiry of Yamanouchi’s SPC for tamsulosin on February 1, 2006 was also recorded in the PDJ. Tamsulosin, marketed as Harnal and Flomax, is an oral treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)...
  • Following on from the decision of both Pfizer and Ranbaxy to appeal the judgement in their atorvastatin case covering EP247633 and EP409281 in the UK, the PDJ records a counterclaim for revocation of SPC GB97/011 being lodged at the Appeals Court...
  • Novacta Biosystems has filed a UK initial application disclosing improvements relating to lantibiotics...
  • Delta G has also filed a UK application, apparently its first, which may relate to a biochemical mechanism for chronic fatigue syndrome (CFS)...
  • UK initial (“A0”) applications filed January 11th - 18th 2006
Week 07:
  • The UK Patents and Designs Journal (PDJ No. 6091) does not contain any SPC news this week. However, the revocation of EP915899, Abbott’s patent entitled Preparation of crystal form II of clarithromycin, was announced...
  • We do not often comment on patenting in Iceland, but the February Icelandic Gazette (ELS) contains a rather strange SPC application. This application by Warner Lambert Company LLC (i.e. Pfizer) requests a certificate for pregabalin (Lyrica)...
  • Although the UK PDJ does not contain any new SPC information a further three applications were filed in January that have not yet appeared in the PDJ. Two of these from Bayer and Astellas...
  • Avidex Ltd is seeking protection for T cell receptor-based hypersensitivity therapeutics. The company exploits unique ways of making recombinant protein versions of T cell receptors (TCRs)...
  • Britannia Pharmaceuticals Ltd is claiming the use of phospholipids as a selective pulmonary barrier layer. A subsidiary of Ajinomoto, the Surrey-based company is a supplier of innovative products for niche medical conditions and has developed treatments for asthma, Parkinson's disease and erectile dysfunction...
  • UK initial (“A0”) applications filed January 4th - 11th 2006
Week 06:
  • The UK Patents and Trademarks Journal (PDJ) this week reports the entry into force of the SPC based on EP0193256 protecting pioglitazone...
  • Three weeks ago in Current Patents Gazette (CPG 0603), we reported the agreement between Cephalon and Mylan regarding the settlement of their Provigil ® (modafinil) litigation on January 10. This followed similar agreements with Ranbaxy and Teva...
  • In the same announcement Cephalon and Barr settled their disagreement over Cephalon’s Actiq (oral transmucosal fentanyl citrate)...
  • UK initial (“A0”) applications filed December 23rd 2005 - January 4th 2006
Week 05:
  • A year ago, in the Current Patents Gazette (CPG) 0505 we reported that the SPC for flosequinan on EP149519 had entered into force on January 7, 2005. The quoted expiry was August 9, 2007...
  • The SPC on EP0034415 for Johnson & Johnson’s levocabastine is also reported as having expired. Levocabastine, an OTC product marketed as Livostin or Livocarb...
  • In addition to the granted extensions reported in last week’s CPG, forty new extension applications were published in January’s Japanese gazette. Six of these covered the use of lamividune, alone or in combination with adefovir pivoxil, whilst a further one covers lamivudine with abacavir sulphate. Emory University...
  • NovaBiotics Limited filed an initial application entitled “therapeutic peptides”. The Aberdeenshire-based company registered with companies’ house in 23/08/2004 and this appears to be the first patenting to be observed from this company...
  • UK initial (“A0”) applications filed December 15th - December 28th 2005
Week 04:
  • Warner Lambert’s UK SPC for GSK’s acrivastine plus pseudoephedrine antihistamine/-decongestant product based on EP0085959, was reported in this weeks UK Patents and Designs Journal (PDJ No. 6088)...
  • It was also reported in the PDJ that Elan Pharmaceuticals had been granted an SPC based on EP0835126 for their ziconotide product, marketed as Prialt...
  • The first UK SPC application of 2006 has also been filed, although this has not yet been reported in the PDJ. Syngenta filed an application on January 13 for the herbicide pinoxaden...
  • The Japanese patent gazette for January, published January 25th, reported that extensions of 5 years have been granted to Boehringer Ingelheim...
  • Several interesting new chemical applications were published this week. Plexxikon filed WO2006009755 and WO2006009797 relating to benzylpyridine-2-amines as c-kit transduction modulators...
  • Sienabiotech (SIBI) published its first patent application, WO2006008133, relating to Alpha7 nAChR agonists for the treatment of CNS disorders...
  • Tetrahedron SAS, a small biotech company based just outside Paris published an application relating to selenium-based compounds...
  • UK initial (“A0”) applications filed November 17th - December 20th 2005
Week 03:
  • The French Official Bulletin (BOPI 06/02) of January 13, 2006 (which did not appear this week on the internet until January 19th ) contained details of the filing by Protein Design Labs of their application for a French SPC on EP451216 for omalizumab...
  • Followers of drug patent litigation may have noticed a recent Press Release from Cephalon announcing an agreement with Mylan Pharmacueticals, regarding the settlement of their Provigil ® (modafinil) litigation...
  • Over the last couple of weeks it has been rumoured that Europe's two leading pharmaceutical companies, GSK and Novartis are deliberating take-over bids for Serono, the maker of the multiple sclerosis treatment, Rebif...
  • UK initial (“A0”) applications filed January 6th - January 14th 2006
Week 02:
  • Genentech’s bevacizumab (Avastin), which is approved for use in the treatment of colorectal cancer, was the only granted SPC reported in the UK Patents and Designs Journal (PDJ No. 6086) this week...
  • Orion Corporation’s SPC application for Stalevo (a combination of levodopa, carbidopa and entacapone) was reported to be withdrawn on November 11, 2005. No indication of the reason for the withdrawal was given...
  • The SPC on EP186087, the EU product patent for pramipexole, co-marketed and developed by Boehringer Ingelheim and Pharmacia as Mirapex for the treatment of the signs and symptoms of idiopathic Parkinson’s disease...
  • On the same day the SPC for risedronate (Actonel) came into force also expiring December 15, 2010...
  • Neurogen’s application, WO2006004589, was published this week outlining novel inhibitors of the C5a-CD88 interaction initially described in the abstract as MMP or ADAM modulators...
  • UK initial (“A0”) applications filed November 30th - December 8th 2005
Week 01:
  • The entry into force of the SPC on EP186833 for adalimumab on December 13, 2005 is reported in the first UK Patents and Designs Journal (PDJ) of 2006. This starts the final 5 years protection for Yeda on this process patent...
  • Several recently expired SPCs are reported in the PDJ, including Takeda's lansoprazole SPC which we mentioned in last weeks Current Patents Gazette. Another of Abbott's major drugs, sevoflurane, loses the protection of a process patent...
  • The SPC obtained by Hokuriku Pharmaceuticals (now part of Abbott) relating to lomefloxacin based on EP0140116 expired December 12th. Lomefloxacin is marketed by Pfizer (originally Searle) as Maxaquin in most markets, although Unimed (now part of Solvay) obtained the US rights...
  • The Japanese gazette for December contained details of a five year extension granted to Nihon Medi-Physics for 123-I iomazenil on JP1996926 (JP07033387) which now expires August 2014. Nihon Medi-Physics is developing the benzodiazepine receptor ligand...
  • UK initial (“A0”) applications filed November 24th - November 30th 2005
Back to top




 
 
Disclaimer | Terms of Use
Privacy Policy | Copyright 		Home | Contact Us | About Us | Press Room | Products | Customer Service
Support | Free Resources | Site Map | Careers